Scilex Holding (SCLX) Net Equity Issued and Repurchased (2020 - 2024)
Scilex Holding (SCLX) posted quarterly Net Equity Issued and Repurchased of $15.0 million for Q2 2024, up 1001.98% year-over-year from $1.4 million in Q3 2023, and up 50.0% quarter-over-quarter from $10.0 million in Q1 2024.
Scilex Holding (SCLX) Net Equity Issued and Repurchased (2020 - 2024) Analysis & Trends
Scilex Holding's Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $15.0 million for Q2 2024.
- In Q2 2024, Net Equity Issued and Repurchased rose 1001.98% year-over-year to $15.0 million; the TTM figure through Sep 2024 stood at $60.5 million (changed N/A YoY), while the FY2023 annual figure was $35.5 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased for Q2 2024 stood at $15.0 million, up from $10.0 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $135.6 million in Q1 2021, with the low at -$135.6 million in Q3 2021.
- The 4-year median for Net Equity Issued and Repurchased is $5.8 million (2023), against an average of $6.0 million.
- The sharpest annual moves came in 2021 and 2024: Net Equity Issued and Repurchased plunged 542500.0% in 2021, then jumped 1001.98% in 2024.
- Scilex Holding's Net Equity Issued and Repurchased stood at $25000.0 in 2020, then slumped by 542500.0% to -$135.6 million in 2021, then soared by 126.15% to $35.5 million in 2023, then plunged by 57.7% to $15.0 million in 2024.
- Business Quant data shows SCLX's Net Equity Issued and Repurchased at $15.0 million in Q2 2024, $10.0 million in Q1 2024, and $35.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 9.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 15.00 Mn |
| Jun 30, 2024 | 15.00 Mn |
| Mar 31, 2024 | 10.00 Mn |
| Mar 31, 2024 | 10.00 Mn |
| Dec 31, 2023 | 35.46 Mn |
| Dec 31, 2023 | 35.46 Mn |
| Jun 30, 2023 | -1.66 Mn |
| Jun 30, 2023 | -1.66 Mn |
| Mar 31, 2023 | 1.66 Mn |
| Mar 31, 2023 | 1.66 Mn |
| Dec 31, 2021 | -135.60 Mn |
| Dec 31, 2021 | -135.60 Mn |
| Sep 30, 2021 | -135.60 Mn |
| Sep 30, 2021 | -135.60 Mn |
| Jun 30, 2021 | 135.60 Mn |
| Jun 30, 2021 | 135.60 Mn |
| Mar 31, 2021 | 135.60 Mn |
| Mar 31, 2021 | 135.60 Mn |
| Dec 31, 2020 | 25,000.00 |
| Dec 31, 2020 | 25,000.00 |